	US 12,473,371 B2
	Anti-OPG antibodies
Joana De Abreu Carvalho, Cambridge (GB); Steve Holmes, Cambridge (GB); and Allan LAwrie, South Yorkshire (GB)
Assigned to KYMAB LIMITED, Cambridge (GB)
Filed by KYMAB LIMITED, Cambridge (GB)
Filed on May 5, 2023, as Appl. No. 18/312,897.
Application 18/312,897 is a division of application No. 16/480,903, granted, now 11,680,101, previously published as PCT/EP2018/052017, filed on Jan. 26, 2018.
Claims priority of application No. 1701416 (GB), filed on Jan. 27, 2017; and application No. 1717006 (GB), filed on Oct. 16, 2017.
Prior Publication US 2024/0026020 A1, Jan. 25, 2024
Int. Cl. A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 9/12 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2878 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 9/12 (2018.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01)]

3 Claims

1. A method of treating a disease or disorder in a patient in need thereof, comprising administering to the patient an effective amount of an antibody or antigen binding fragment thereof that specifically binds to human osteoprotegerin (hOPG), thereby treating the disease or disorder in the patient; wherein the disease or disorder is systemic hypertension, resistant hypertension, pulmonary hypertension (PH), or pulmonary arterial hypertension (PAH); and

wherein the antibody or antigen binding fragment thereof that specifically binds to human osteoprotegerin (hOPG) comprises a heavy chain variable region (VH) and a light chain variable region (VL), comprising:

(a) the CDRH1 amino acid sequence of SEQ ID NO: 46 or SEQ ID NO: 49, the CDRH2 amino acid sequence of SEQ ID NO: 47 or SEQ ID NO: 50, the CDRH3 amino acid sequence of SEQ ID NO: 48 or SEQ ID NO: 51; and

(b) the CDRL1 amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 59, the CDRL2 amino acid sequence of SEQ ID NO: 57 or SEQ ID NO: 60, and the CDRL3 amino acid sequence of SEQ ID NO: 58 or SEQ ID NO: 61.